Review Explores Modern Drug Strategies for Obesity Management and Future Directions

The global obesity epidemic is a major public health crisis, with an estimated 1.9 billion adults overweight and roughly 650 million living with obesity. This condition is strongly linked to severe metabolic consequences, including increased risk of type 2 diabetes mellitus (T2DM), cardiovascular disease, and certain cancers. Anti-obesity medications offer a crucial strategy by addressing the complex factors contributing to obesity, but their landscape is rapidly evolving. This review synthesizes the broad classes of medications, particularly incretin-based therapies, and their potential role in addressing the global obesity epidemic, highlighting current trends and future perspectives.